Ren Li, Wang Jie, Feng Ling, Wang Shuli, Li Jun
Department of Cardiovascular, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Evid Based Complement Alternat Med. 2018 Mar 27;2018:9745804. doi: 10.1155/2018/9745804. eCollection 2018.
Suxiao jiuxin pill is considered an effective ancillary drug in patients with coronary heart disease. Although numerous small, single-center clinical trials have been conducted, the benefits and harms of suxiao jiuxin pill remain controversial. We performed a meta-analysis to clarify the efficacy of suxiao jiuxin pill on patients with coronary heart disease. Randomized controlled trials were identified by using the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases (until June 2016). Pooled relative risks (RR), weighted mean differences (WMD), and 95% confidence intervals (95% CIs) were estimated using random-effects models. Forty-one trials involving 6276 patients were included in our analysis. Administration of suxiao jiuxin pill significantly improved electrocardiogram (ECG) results when compared with other therapies (RR 1.32, 95% CI 1.26 to 1.38, and < 0.001). Subgroup analyses revealed that suxiao jiuxin pills improve ECG results more than salvia tablets (RR 1.54, 95% CI 1.41 to 1.67, and < 0.001), isosorbide dinitrate (RR 1.14, 95% CI 1.21 to 1.44, and = 0.001), nitroglycerin (RR 1.35, 95% CI 1.16 to 1.56, and < 0.001), and other drugs (RR 1.32, 95% CI 1.21 to 1.44, and < 0.001). Available evidence additionally suggests that suxiao jiuxin pills could significantly reduce total cholesterol (WMD -0.62 mmol/L, 95% CI -1.06 to -0.18 mmol/L, and = 0.005) and low-density lipoprotein (LDL) levels (WMD -1.12 mmol/L, 95% CI -1.42 to -0.82 mmol/L, and < 0.001) and increase high-density lipoprotein (HDL) levels (WMD 0.32 mmol/L, 95% CI 0.07 to 0.58 mmol/L, and = 0.014). However, no significant differences were observed in total triglyceride levels, plasma viscosity, hematocrit, and fibrinogen. No incidences of adverse reactions were observed after administration of suxiao jiuxin pill. Improvements in ECG results and lipid profiles were also observed after suxiao jiuxin administration compared to other therapies. It also decreased low-cut and high-cut whole blood viscosity without significant adverse reactions.
速效救心丸被认为是冠心病患者有效的辅助药物。尽管已经进行了大量小型单中心临床试验，但速效救心丸的利弊仍存在争议。我们进行了一项荟萃分析，以阐明速效救心丸对冠心病患者的疗效。通过使用Cochrane图书馆、PubMed、Web of Science、Embase、万方、维普和中国知网数据库（截至2016年6月）检索随机对照试验。使用随机效应模型估计合并相对风险（RR）、加权平均差（WMD）和95%置信区间（95%CI）。我们的分析纳入了41项试验，涉及6276例患者。与其他疗法相比，服用速效救心丸显著改善了心电图（ECG）结果（RR 1.32，95%CI 1.26至1.38，P<0.001）。亚组分析显示，速效救心丸比丹参片（RR 1.54，95%CI 1.41至1.67，P<0.001）、硝酸异山梨酯（RR 1.14，95%CI 1.21至1.44，P = 0.001）、硝酸甘油（RR 1.35，95%CI 1.16至1.56，P<0.001）和其他药物（RR 1.32，95%CI 1.21至1.44，P<0.001）更能改善心电图结果。现有证据还表明，速效救心丸可显著降低总胆固醇（WMD -0.62 mmol/L，95%CI -1.06至-0.18 mmol/L，P = 0.005）和低密度脂蛋白（LDL）水平（WMD -1.12 mmol/L，95%CI -1.42至-0.82 mmol/L，P<0.001），并提高高密度脂蛋白（HDL）水平（WMD 0.32 mmol/L，95%CI 0.07至0.58 mmol/L，P = 0.014）。然而，在总甘油三酯水平、血浆粘度、血细胞比容和纤维蛋白原方面未观察到显著差异。服用速效救心丸后未观察到不良反应事件。与其他疗法相比，服用速效救心丸后心电图结果和血脂谱也有改善。它还降低了低切和高切全血粘度，且无明显不良反应。
